MedCity News

Debunking the Myths Around Patient Financing

By John Talaga

Which AI Applications Interest Your Employer Clients the Most? Where Will They Have the Greatest Impact?

If you advise self-insured employers on healthcare benefits, your expert insights will help provide a comprehensive perspective of the state of healthcare benefits for employers in our second annual survey, the 2024 Benefit Consultant Sentiment THE INDEX.

By MedCity News

BioPharma, Pharma

Regeneron Bets $100M That Mammoth’s CRISPR Tech Can Deliver on Next Wave of Genetic Medicines

Regeneron Pharmaceuticals is collaborating with CRISPR technologies startup Mammoth Biosciences to develop in vivo gene-editing therapies. The deal marks the third pharmaceutical industry partnership for Mammoth, which initially focused on developing CRISPR-based diagnostics.

By Frank Vinluan

MedCity Influencers

Examining the Usefulness of the Lean Startup Method in Building Health Tech Products

How health tech startups can successfully adapt the principles to their business ideas

By Rachel Kuperman

Latest News

MedCity Influencers

With All the Organ Donation Scrutiny, Ask: What Can We Do to Reduce the Need?

People do not have to die waiting for a kidney. A VBC approach can lead to earlier identification of kidney disease and better management in its earlier stages.

By George Hart

Providers, Legal

Providence Ordered to Pay $200M for ‘Systemic Wage Violations’

More than 33,000 Providence employees filed a class-action complaint against the health system in 2021, alleging that it had been withholding their wages by denying them breaks and rounding down their working hours. Last week, Providence was ordered to pay more than $200 million in damages — a decision that “sends a message to healthcare corporations,” according to an attorney representing the workers.

By Katie Adams

BioPharma, Pharma

FDA Drug Approval Marks a New Day for Treating Pediatric Brain Cancer

Day One Biopharmaceuticals drug Ojemda is now FDA-approved for advanced pediatric low-grade glioma, the most common type of brain cancer in children. The regulatory decision for Ojemda covers a broader swath of patients than a drug combination from Novartis approved for treating this childhood cancer.

By Frank Vinluan

MedCity Influencers, Patient Engagement

It’s Time to Give Patients a Seat at the Table

Game-changing advances can be achieved by integrating patient collaboration and priorities into the full span of trial design.

By Chris Boone

MedCity Influencers

To Further Impede the Progression of Heart Disease, We Must Treat Patients With Anti-Inflammatory Drugs in Combination With Statin Therapy

it is paramount that we address both cholesterol risk and inflammation to reduce the risk of a heart attack or stroke.

By Robert Quigley

Consumer / Employer

Health Benefit Consultants, Share Your Expert Insights in Our Survey

Share some of the trends you are seeing among your clients across healthcare, including chronic conditions, behavioral health, healthcare navigation, and more.

By MedCity News

Artificial Intelligence

FTC Chief Says Tech Advancements Risk Healthcare Price Fixing

Algorithms make it possible for companies to fix prices without explicitly coordinating with one another, posing a new test for regulators policing the market, said Lina Khan, chair of the Federal Trade Commission, during a media event hosted by KFF.

By Julie Rovner, KFF Health News and David Hilzenrath

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

By PurpleLab

MedCity Influencers

Patient Engagement Is Essential for Achieving the Goals of Value-Based Care

Success requires both novel VBC models as well as moving care beyond the clinic walls to meet patients where they are.

By Jason Helgerson and Glen Moller

BioPharma

Six Biopharma Companies to Watch at MedCity INVEST Pitch Perfect Contest

The MedCity INVEST conference is scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, The companies will offer a window into some of the promising treatments under development such as different types of cancers to muscular dystrophy. Space is limited so register today!

By Stephanie Baum

Health Tech

Why Headspace Is Launching Direct-to-Consumer Services

Headspace is going toe-to-toe with the likes of Talkspace and BetterHelp by bringing its mental health services directly to consumers — starting with text-based mental health coaching.

By Katie Adams

BioPharma, Pharma

FDA Approves Immunotherapy That Can Spare Bladder Cancer Patients From Radical Surgery

ImmunityBio therapy Anktiva is now FDA approved for treating patients with non-muscle invasive bladder cancer. The novel immunotherapy works by sparking activity from three types of immune cells.

By Frank Vinluan

MedCity Influencers

Don’t Let Inflation Bloat Your Drug Spending

Smart but easy tech upgrades can boost margins.

By AJ Rivosecchi

Daily, MedCity Influencers

Collaboration Now: Maximizing AI’s Potential in the Industry it Matters Most

No passing fad, AI in healthcare is here, and it’s already improving the lives of patients, healthcare workers, and researchers. How can we make a good thing even better?

By Itai Rechnitz

Daily

Neurodivergent Masking: A Hidden Contributor to the $2-Trillion Burnout Crisis

It can be tiring pretending to be someone you’re not. For many neurodivergent people at work, this is an everyday reality — and it’s burning them out.

By Ed Thompson

BioPharma, Startups

Takeda, Astellas & Sumitomo Mitsui Form Joint Venture to Lift Japanese Innovation From ‘Valley of Death’

Two Japanese pharmaceutical companies and a bank are teaming up to form a joint venture to advance therapeutic discoveries from academia. The focus will be innovation from universities in Japan.

By Frank Vinluan